Efficacy of Taletrectinib in Patients with Advanced ROS1 Fusion-Positive NSCLC By Ogkologos - April 18, 2025 936 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from an integrated analysis of the pivotal phase II regional TRUST-I and global TRUST-II studies Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Relacorilant Annual Multicancer Early Detection Test Not Associated with a Lower Incidence Rate of Stage III or IV Cancer After Three Screening Rounds and 12... ESMO welcomes the adoption of European Parliament Report on Europe’s Beating Cancer Plan in the Committee on Public Health (SANT), calls for further EU... MOST POPULAR Study Finds Most Women Who ‘Go Flat’ After Mastectomy Are Happy... January 16, 2021 EMA Recommends Granting a Conditional Marketing Authorisation for Selumetinib April 30, 2021 Analysis Shows Women with High Breast Cancer Recurrence Scores Benefit from... October 24, 2019 A Genome-Wide Association Study of irAEs Identifies New Genome-Wide Significant Associations... January 20, 2023 Load more HOT NEWS Young Mom Of Two Survived Breast Cancer, Heart Failure, And Two... Selpercatinib Shows Durable Efficacy in RET Fusion–positive NSCLC FDA Approves Pembrolizumab or Pembrolizumab and Berahyaluronidase alfa-pmph Each with Enfortumab... FDA Approves Amivantamab-vmjw with Carboplatin and Pemetrexed for Non-Small Cell Lung...
